

1 **A genome-wide CRISPR screen in *Anopheles* mosquito cells identifies**
2 **essential genes and required components of clodronate liposome**
3 **function**

4 Enzo Mamei^{1#}, George-Rafael Samantsidis^{2#}, Raghuvir Viswanatha¹, Hyeogsun Kwon²,
5 David R. Hall², Matthew Butnaru¹, Yanhui Hu¹, Stephanie E. Mohr¹, Norbert Perrimon^{1,3*},
6 Ryan C. Smith^{2*}

7 ¹Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA,
8 02115, USA

9 ²Department of Plant Pathology, Entomology and Microbiology, Iowa State University,
10 Ames, IA 50011, USA

11 ³HHMI, Harvard Medical School, Boston, MA, 02115, USA

12 #These authors contributed equally and are listed alphabetically

13 *To whom correspondence should be addressed: perrimon@genetics.med.harvard.edu;
14 smithr@iastate.edu

15 **Abstract**

16 *Anopheles* mosquitoes are the sole vector of human malaria, the most burdensome
17 vector-borne disease worldwide. Strategies aimed at reducing mosquito populations and
18 limiting their ability to transmit disease show the most promise for disease control.
19 Therefore, gaining an improved understanding of mosquito biology, and specifically that
20 of the immune response, can aid efforts to develop new approaches that limit malaria
21 transmission. Here, we use a genome-wide CRISPR screening approach for the first time
22 in mosquito cells to identify essential genes in *Anopheles* and identify genes for which
23 knockout confers resistance to clodronate liposomes, which have been widely used in
24 mammals and arthropods to ablate immune cells. In the essential gene screen, we
25 identified a set of 1280 *Anopheles* genes that are highly enriched for genes involved in
26 fundamental cell processes. For the clodronate liposome screen, we identified several
27 candidate resistance factors and confirm their roles in the uptake and processing of
28 clodronate liposomes through *in vivo* validation in *Anopheles gambiae*, providing new
29 mechanistic detail of phagolysosome formation and clodronate liposome function. In
30 summary, we demonstrate the application of a genome-wide CRISPR knockout platform
31 in a major malaria vector and the identification of genes that are important for fitness and
32 immune-related processes.

33 **Introduction**

34 Mosquitoes are essential vectors for the transmission of a variety of bacterial, viral, and
35 parasitic pathogens that cause significant socioeconomic burden and mortality across the
36 globe¹⁻³. Among mosquito-borne diseases, malaria causes more than 200 million clinical
37 cases and 600,000 deaths every year⁴, and is transmitted exclusively through the bite of
38 an *Anopheles* mosquito. As a result of their public health importance, mosquitoes have
39 become an emerging model system to examine aspects of development⁵, blood-feeding
40 physiology⁶, vector-pathogen interactions⁷, and gene-drive technologies⁸; each with the
41 ultimate goal of developing approaches to reduce the devastating impacts of mosquito-
42 borne disease transmission.

43 There has been significant progress in our biological understanding of mosquito species
44 through the development of genetic tools utilizing RNAi⁹, transgenesis^{10,11}, and site-
45 directed mutagenesis¹²⁻¹⁵. However, these reverse-genetic approaches only enable the
46 investigation of candidate gene phenotypes. In contrast, the development of forward-
47 genetic screen technologies would make it possible to associate genes with phenotypes
48 in an unbiased manner and thereby uncover mosquito-specific as well as conserved gene
49 functions. CRISPR gene editing technology has made it easier to perform genetics in
50 mosquitos and other non-model species¹⁶, and CRISPR technologies are being applied
51 as an *in vivo* research tool and potential intervention in mosquito populations, including
52 mosquitoes of the *Anopheles* genus^{17,18}. What has remained lacking, however, is an
53 efficient system for genome-wide forward genetic screening using CRISPR or other
54 similar technologies.

55 To address this need, we recently developed a platform for pooled-format CRISPR
56 screening in mosquito cells, based on the CRISPR screen platforms we developed for
57 *Drosophila* S2R+ cells^{19,20}. For this approach, we use recombination mediated cassette
58 exchange (RMCE) to integrate single guide RNAs (sgRNAs) into the genome, making it
59 possible to later associate screen assay phenotypes with genotypes. Application of this
60 approach in *Drosophila* cells has resulted in the identification of essential genes^{19,21}, a
61 novel transporter for the insect hormone ecdysone²², and receptors of bacterial toxins²³.
62 To extend this approach to *Anopheles*, we first engineered the *Anopheles* Sua-5b cell line

63 with attP sites for RMCE and stable expression of Cas9 (i.e., a ‘screen-ready’ cell line);
64 identified pol III promoters for sgRNA expression in *Anopheles* cells; and developed an
65 approach to sgRNA design for screens in *Anopheles* Sua-5b cells. Then, in a pilot study,
66 we introduced into the screen-ready Sua-5b cells a library of 3,487 sgRNAs and screened
67 for cells resistant to treatment with rapamycin, ecdysone, or trametinib²⁴. As expected,
68 we were able to precisely and efficiently identify the *Anopheles* orthologs of the targets of
69 these treatments²⁴, opening the doors for the first time to application of large-scale
70 forward-genetic screening in *Anopheles* cells.

71 One of our goals in developing the genome-wide cell screening platform was to contribute
72 to our understanding of mosquito immune responses and cellular immune function²⁵.
73 Mosquito immune cells, known as hemocytes, are essential components of the innate
74 immune system²⁶ and have integral roles in shaping mosquito vector competence to both
75 arbovirus^{27,28} and malaria parasite infection^{29–33}. With few genetic resources available for
76 the *in vivo* study of mosquito hemocytes, we recently adapted the use of clodronate
77 liposomes, which have traditionally been used in mammalian systems for macrophage
78 depletion^{34,35}, to chemically ablate macrophage-like immune cell populations across
79 arthropod species^{32,36,37}. This methodology has been instrumental to our growing
80 understanding of the role of macrophage-like granulocyte populations in mosquitoes and
81 their contributions to host survival and pathogen infection outcomes^{28,32,36}. However,
82 despite the widespread use of clodronate liposomes in vertebrate and invertebrate
83 systems, we still lack a mechanistic understanding of how they gain entry and are
84 processed to promote targeted cell ablation. We reasoned that the application of a
85 genome-wide CRISPR screen has the potential to identify factors that are required for
86 clodronate liposome-mediated cell ablation, providing a methodology to better
87 understand clodronate liposomes as a research tool.

88 Herein, we perform genome-wide CRISPR screens in an *Anopheles* mosquito cell line
89 that identify ~1300 essential genes responsible for cell viability and growth, as well as
90 discern several genes involved in the uptake and processing of clodronate liposomes that
91 provide novel insights into the mechanism by which they promote cell ablation. These
92 results demonstrate the potential of forward-genetic screens in mosquito cell lines that

93 have important implications for advancing our understanding of cellular immune function
94 and the development of new mosquito control strategies.

95 **Results**

96 **Genome-wide CRISPR knockout screen to identify essential genes in *Anopheles***

97 To extend the pooled screen approach to genome-wide scale, we first cloned a library of
98 89,711 unique sgRNAs targeting 93% of *Anopheles* genes, with ~96% of these genes
99 targeted by 7 sgRNAs per gene based on our previously reported sgRNA design resource
100 for this species²⁴ (**Fig. 1a** and **1b**). This set was supplemented with positive and negative
101 control sgRNAs and others, resulting in a total library of 90,208 sgRNAs (**Supplementary**
102 **Table 1**). We then introduced the library into CRISPR 'screen-ready' (attP+, Cas9+)
103 *Anopheles* Sua-5b cells²⁴ in the presence of Φ C31 integrase to generate a pool of
104 knockout (KO) cells (**Fig. 1a**). Our first goal for genome-wide screening was to use a
105 'dropout' assay (negative selection assay) to identify genes for which knockout results in
106 decreased fitness, growth arrest, and/or cell death (hereafter, "essential genes"). After 8
107 weeks of outgrowth of the KO cell pool, we compared the relative abundance of each
108 sgRNA in the outgrowth pool to the distribution of sgRNAs in the starting plasmid library
109 by NGS followed by MAGeCK MLE analysis³⁸ (**Supplementary Table 2**). Using the
110 relationship between gene expression and Z-score rank, we identified 1280 putative
111 essential genes with 95% confidence (FDR=0.05) (**Fig. 1c**). As expected, the majority of
112 guides targeting genes annotated as components of the cytoplasmic or mitochondrial
113 ribosome, the spliceosome, or the proteasome have negative Z-scores, consistent with
114 essentiality in this assay (**Fig. 1d**).

115 To further examine the essential gene data set, we first identified *Drosophila* orthologs of
116 the *Anopheles* genes identified in the screen, then performed gene set enrichment
117 analysis (GSEA) using PANGEA³⁹, a gene set enrichment tool that includes query of
118 manually curated annotations for *Drosophila* (**Supplementary Fig. 1** and
119 **Supplementary Table 2**). We performed GSEA using generic gene ontology (GO) terms
120 for biological process⁴⁰ and as expected, found that the gene list is enriched for
121 fundamental cellular processes such as DNA and RNA metabolism and cell cycle

122 components (**Supplementary Fig. 1**). Next, we analyzed the list using as a reference the
123 curated Gene List Annotation for *Drosophila* (GLAD) resource⁴¹ and similarly identified
124 gene groups corresponding to fundamental activities or structures, e.g. components of
125 the ribosome, proteasome, and spliceosome (**Supplementary Fig. 1**). Finally, we used
126 PANGEA to perform GSEA using as a reference a set of phenotypes associated with
127 classical mutations as annotated by FlyBase⁴². Consistent with our expectations, the top-
128 enriched phenotype is “cell lethal.” In addition, we found other enriched cell phenotypes,
129 including “decreased occurrence of cell division,” “abnormal cell cycle,” and “abnormal
130 cell size” (**Supplementary Fig. 1**).

131 Strikingly, we identified a single gene, *ypsilon schachtel* (*yps*) (AGAP006108;
132 FBgn0222959), a ribonucleoprotein complex component⁴³, that appears to limit cell
133 growth in both *Anopheles* and *Drosophila* cells¹⁹, as suggested by the notable growth
134 advantage in *yps* knockout cells (**Fig. 1e**, upper-right quadrant). Included among the
135 *Anopheles* genes that negatively impacted growth, we identified the ortholog of
136 *Drosophila serpent* (*srp*; AGAP002238; FBgn0003507), a GATA transcription factor
137 involved in *Drosophila* hematopoiesis^{44,45}. When *srp* was silenced *in vivo* in adult female
138 *Anopheles gambiae*, we see reduced hemocyte numbers and increased malaria parasite
139 infection (**Supplementary Fig. 2**), supporting that *srp* has similar roles in mosquito
140 hematopoiesis and immune function.

141 **Comparison with essential gene screen data from *Drosophila* and human cells**

142 As a data quality analysis step, we next compared putative essential genes identified in
143 this screen with essential genes identified in a similar screen in *Drosophila*²¹. To do this,
144 we first mapped *Anopheles* genes to *Drosophila* orthologs using DIOPT (v 9.0) and
145 filtered the results based on the DIOPT score. For genes in each ortholog pair, we
146 graphed the corresponding Z scores and found a high degree of overlap between genes
147 that scored as essential in the two species (**Fig. 1e**, lower-left quadrant), supporting the
148 validity of the results of the essential gene screening platform in *Anopheles* cells. We next
149 used the list of *Drosophila* orthologs to ask how many genes are in common in the
150 *Anopheles* essential gene list and a similar list generated using an optimized CRISPR
151 knockout screen platform in *Drosophila* S2R+²¹. The 1280 mosquito genes map to 1213

152 *Drosophila* genes and of these, 88% (1073/1213) were identified as essential in the
153 *Drosophila* cell screen (**Supplementary Table 3**).

154 The results of comparison of essential genes in *Anopheles* and *Drosophila* cell screen
155 datasets suggests that many of the genes are generally required for cell growth and
156 viability but is confounded by the fact that both *Anopheles* Sua-5b and *Drosophila* S2R+
157 cell lines are considered hemocyte-like (blood-like) cell types, such that conserved factors
158 essential for insect cell hemocytes could be included in both lists. To explore this further,
159 we next mapped genes on the *Anopheles* essential gene list to human orthologs, and
160 asked how many of these genes are included in a core list of 684 human cell-essential
161 genes compiled based on data from 17 human cell knockout screens⁴⁶. The 1280
162 *Anopheles* essential genes mapped to 1185 human orthologs and of these, 34%
163 (398/1185) are among the core human essential genes (**Supplementary Table 3**),
164 suggesting that these 398 genes are conserved genes essential in distantly related
165 metazoan cells.

166 **Genome-wide CRISPR screen for resistance to clodronate treatment**

167 Recent studies have demonstrated the use of clodronate liposomes as a valuable tool to
168 probe cellular immune function in arthropods^{32,36,37}, yet at present, we lack a fundamental
169 understanding of how they function. Even in vertebrate systems, where clodronate
170 liposomes have been more widely used^{34,35}, there is only limited mechanistic information
171 as to how these particles function⁴⁷. As a result, we reasoned that screening for resistance
172 to clodronate liposome-mediated cell ablation in *Anopheles* Sua-5b cells, a hemocyte-like
173 cell line⁴⁸, could reveal important factors relevant to clodronate liposome function in
174 mosquito immune cells. To initiate a genome-wide clodronate liposome selection-based
175 screen, we first tested the effects of treatment of screen-ready Sua-5b cells with a range
176 of concentrations of clodronate liposomes or control (empty) liposomes to determine the
177 appropriate concentrations for a selection-based screen (**Fig. 2a**). We found that the IC50
178 of the clodronate liposomes for Sua-5b cells was 7.4 μ M, whereas the IC50 of control
179 liposomes was approximately 11-fold higher (81.6 μ M; **Fig. 2a**). To perform the screen,
180 we subjected a pooled library of Sua-5b KO cells to continuous selection with clodronate
181 liposomes (“Clodronate A” group), treated them for 4 days with clodronate liposomes then

182 followed by outgrowth in standard media (“Clodronate B” group), or treated them
183 continuously with control liposomes for a total of three cycles of treatment/outgrowth (**Fig.**
184 **2b**). Following the last cycle of outgrowth, we used deep amplicon sequencing and
185 MAGeCK analysis³⁸ to compare sgRNA abundance in each of the two experimental and
186 the control population (**Supplementary Table 4**).

187 To identify candidate genes involved in clodronate uptake and/or processing, we
188 compared the liposome control to the clodronate treatment groups (i.e., we compared
189 Clodronate A or Clodronate B treatments to the liposome control). We were able to
190 identify genes enriched in the experimental groups (**Fig. 2c**). The top-scoring gene in the
191 continuous treatment (Clodronate A) group is a predicted *Anopheles* ortholog of the
192 mammalian GALM (AGAP008154), whereas the top-scoring gene in the Clodronate B
193 group is a predicted ortholog of mammalian PPP2R1A and Pp2A-29B in *Drosophila*
194 (herein referred to as Pp2A-29B; AGAP009105). While some top-scoring genes were
195 different between the two treatment groups, twelve genes scoring in the top 50 hits were
196 found in common between both screens (**Fig. 2c**). This includes Pp2a-29B, PPME1
197 (AGAP008336), SMCO4 (AGAP003534), RIOK3 (AGAP009993), Inx2 (AGAP001488),
198 PAFAH1B2 (AGAP000939), Tsp3A (AGAP002257), TMEM147 (AGAP008757),
199 FAM117B (AGAP011572), jbug (AGAP007006), caz (AGAP001645), and AGAP011017.
200 To reveal the genetic determinants of clodronate liposome uptake and induced toxicity,
201 we performed similar GSEA analyses as for the essential gene set (**Supplementary**
202 **Table 2**), on the top scoring genes conferring resistance to clodronate liposome treatment
203 from each screen. GSEA was performed with GO biological process terms from standard
204 GO sets (“GO hierarchy” at PANGEA); GO subsets specifically curated for *Drosophila* by
205 Flybase⁴² and the Alliance for Genome Resources⁴⁹ (Slim2); and FlyBase Gene
206 Groups⁵⁰. A common theme that emerged from our GSEAS analysis was the enrichment
207 for methyltransferases and gene sets enriched in the *Drosophila* GO analysis included an
208 “autophagy” gene set (**Fig. S3** and **Supplementary Table 4**).

209 **Optimization of clodronate liposome concentrations and timing of uptake *in vivo***

210 Previous *in vivo* studies using clodronate liposomes in *An. gambiae* were performed using
211 a concentration of ~120 μ M/ml (1:5 dilution)^{32,33,51}, a concentration much higher than the

212 ~8 $\mu\text{M}/\text{ml}$ concentration used herein for our *in vitro* screening experiments (**Fig. 2a**). To
213 confirm that this lower concentration was still able to promote cell ablation *in vivo*, we
214 compared the efficiency of clodronate liposomes at the 1:5 dilution with that of a 1:50
215 dilution (~12 $\mu\text{M}/\text{ml}$; comparable to that used in *in vitro* experiments). Using the
216 expression of *eater* and *Nimrod B2* as a proxy for mosquito immune cell (granulocyte)
217 numbers as previously^{32,33,36,37,51}, both the 1:5 and 1:50 clodronate liposome dilutions
218 were able to promote similar reductions in *eater* and *Nimrod B2* (**Supplementary Fig. 4**),
219 suggesting that both concentrations were equally effective in their ability to reduce
220 mosquito immune cell populations *in vivo*.

221 Similarly, while previous studies have demonstrated the utility of clodronate liposomes to
222 deplete immune cell populations in flies, mosquitoes, and ticks^{32,33,36,37,51}, the precise
223 timing required for phagocyte depletion has not been previously examined. Therefore, we
224 utilized fluorescent liposome particles (LP-DiO) to determine the temporal kinetics of
225 liposome uptake and subsequent phagocyte depletion. When examined at multiple time
226 points after injection, the uptake of fluorescent LP-DiO particles peaked at 6h post-
227 injection (with ~37% of hemocytes LP-DiO⁺), before the percentage of LP-DiO⁺ cells
228 began to decrease over time (**Supplementary Fig. 5**). To validate these findings in the
229 context of clodronate-mediated phagocyte depletion, we performed similar time-course
230 experiments following the injection of control or clodronate liposomes to evaluate the
231 timing needed to initiate phagocyte depletion. When granulocyte numbers were assessed
232 by proxy via qPCR through the expression of *eater* and *Nimrod B2*^{32,33,36,37,51}, there was
233 no effect on granulocyte numbers at 6 hours post-injection, yet by 8 hours there was a
234 significant and sustained reduction in *eater* and *Nimrod B2* transcripts indicative of
235 granulocyte depletion (**Supplementary Fig. 5**). Together, these data suggest that
236 liposome uptake occurs within hours post-injection and that liposomes are quickly
237 processed to promote phagocyte depletion. Since previous studies have only evaluated
238 phagocyte depletion at 24 or 48h post-injection^{32,33,36,37,51}, these data provide greater
239 resolution into the timing of liposome processing, enabling a more precise evaluation of
240 candidate genes identified in our CRISPR screen to examine clodronate liposome
241 function.

242 ***In vivo* validation of candidate genes**

243 We next identified candidates from the CRISPR cell screen (**Fig. 2**) for further validation
244 *in vivo* in *An. gambiae* hemocytes. To do this, the top 50 hits from each replicate (of which
245 12 genes were identified in both screens) were cross-referenced with a previous scRNA-
246 seq of *An. gambiae* hemocytes⁵¹ to confirm their expression in mosquito granulocyte
247 populations (**Fig. 3a**). Candidates were selected for further analysis based on their
248 presence in both screens and predicted functional annotations (**Fig. 2c, Supplementary**
249 **Table 4**). A total of 10 candidates were selected for further validation *in vivo* (**Fig. 3a**)
250 using RNA interference (RNAi). To evaluate the role of each candidate gene, we
251 performed dsRNA injections for all 10 candidate genes, resulting in the successful
252 knockdown of 5 out of the 10 genes (*Tsp3A*; *PGAP6*, AGAP002672; *Traf6*, AGAP003004;
253 *GstD3*, AGAP004382; *TMEM147*) when evaluated at two days post-injection (**Fig. 3b**).
254 Additional experiments to examine gene-silencing at four days post-injection for the
255 remaining candidates similarly failed to induce a knockdown (**Supplementary Fig. 6**),
256 suggesting that these genes are not amenable to gene-silencing.

257 To confirm candidate gene function in clodronate liposome-mediated phagocyte
258 depletion, RNAi was performed in adult female mosquitoes before injection with control
259 or clodronate liposomes. The influence of RNAi on clodronate-mediated granulocyte
260 depletion was then evaluated at 8 or 24 hours via the expression of *eater* and *Nimrod B2*
261 as a proxy of granulocyte numbers^{32,33,36,37,51} (**Fig. 3c**). While clodronate liposome
262 treatment significantly reduced *eater* and *Nimrod B2* expression at both 8- and 24-hours
263 post-injection in dsGFP controls (**Fig. 3d**), silencing of *Tsp3A*, *PGAP6*, *Traf6*, *GstD3*, and
264 *TMEM147* each impaired phagocyte depletion, resulting in higher expression levels of
265 *eater* and *Nimrod B2* when compared to controls (**Fig. 3d**). There was variance amongst
266 the five candidate genes examined in their effects on phagocyte depletion, with the
267 silencing of *Traf6* displaying the weakest phenotype (only affecting *eater* at 8 hours), while
268 *PGAP6* silencing completely inhibited the effects of clodronate liposome treatment at 8
269 and 24 hours for both reporter genes examined (**Fig. 3d**). Together, these phenotypes
270 confirm the role of each candidate gene in clodronate liposome-mediated phagocyte
271 depletion.

272 **Liposome uptake is mediated by phagocytosis**

273 To better understand the roles of our candidate genes and the uptake mechanisms of
274 clodronate liposomes in invertebrate cells, we first examined the influence of endocytic
275 pathways on liposome uptake. Using pharmacological inhibitors that target endocytosis
276 (chlorpromazine, CPZ)^{52–54} or phagocytosis (cytochalasin, CytoD)^{55–58} (**Fig. 4a**),
277 mosquitoes were intrathoracically injected with each inhibitor or 10% DMSO as a control
278 to determine the role of each respective pathway on liposome uptake. When mosquitoes
279 were challenged with LP-DiO particles following inhibitor treatment, the uptake of LP-DiO
280 particles was significantly impaired only in mosquitoes treated with CytoD (**Fig. 4b**),
281 suggesting that liposome uptake is dependent on immune cell phagocytosis. Additional
282 experiments confirm that CytoD treatment impairs phagocyte depletion (**Fig. 4c**),
283 demonstrating that phagocytic function is integral to clodronate liposome-mediated
284 phagocyte depletion.

285 After demonstrating that CytoD treatment impedes phagocytosis *in vivo* (**Fig. 4d**), we
286 sought to address whether any candidate genes identified in the CRISPR screen may
287 similarly influence phagocytosis and liposome uptake. When phagocytosis experiments
288 were performed following RNAi-mediated gene silencing, only the *Traf6*-silenced
289 background displayed notable defects in phagocytic ability (**Fig. 4e**). This suggests that
290 the impairment of clodronate liposome-mediated phagocyte depletion by *Traf6* RNAi
291 (**Figs. 3a and 3d, Supplementary Table 4**) is likely mediated through phagocytic function
292 (**Fig. 4f**). Moreover, the minimal influence of the remaining candidate genes on
293 phagocytosis suggests that their function lies downstream of liposome uptake.

294 **Candidate genes that impair clodronate liposome processing are involved in** 295 **phagolysosome formation**

296 Following phagocytic uptake, internalization results in the formation of an early
297 phagosome that undergoes maturation and ultimately fuses with the lysosome to form a
298 phagolysosome, facilitating pathogen killing and protein degradation^{59–61} (**Fig. 5a**). To
299 better understand how clodronate liposomes are processed following phagocytosis and
300 to identify potential roles of our candidate genes in this process, we again utilized LP-DiO
301 particles to visualize liposome uptake and processing in mosquito immune cells.

302 Approximately 8 hours post-injection, LP-DiO particles colocalize with lysosomes (**Fig.**
303 **5b**), indicating that the normal processing of liposome particles involves the formation of
304 the phagolysosome (**Fig. 5a**). In addition, we observed distinct patterns of DiO localization
305 in immune cells, with some cells displaying punctate DiO localization, suggesting the
306 presence of intact LP-DiO particles (referred to as LP-DiO⁺ cells, **Fig. 5c**), or those that
307 displayed a more diffuse pattern of DiO suggesting the breakdown and release of the LP-
308 DiO particles (referred to as DiO⁺ cells, **Fig. 5d**). When these phenotypes were quantified
309 in our candidate gene backgrounds, both *Tsp3A* and *Traf6* RNAi displayed a significant
310 increase in the accumulation of LP-DiO⁺ cells (**Fig. 5c**). Conversely, silencing of *Tsp3A*,
311 *PGAP6*, and *TMEM147* significantly reduced the percentage of cells that were DiO⁺ (**Fig.**
312 **5d**), suggesting that these RNAi backgrounds were impaired in their ability to breakdown
313 LP-DiO⁺ particles. Together, these data suggest that each of our candidate genes, with
314 the exception of *GstD3*, contribute to the internal processing of liposome particles likely
315 through the formation of the phagolysosome.

316 To further validate this phenotype, we performed additional experiments using
317 Bafilomycin A1 (BAF A1), an inhibitor of lysosome acidification and phagolysosome
318 formation (**Fig. 5a**). Similar to the DiO localization phenotypes observed in **Figs. 5c** and
319 **5d**, BAF A1 treatment significantly increased the percentage of LP-DiO⁺ cells, while
320 reducing the percentage of DiO⁺ cells (**Fig. 5e**). Additional experiments to evaluate
321 clodronate liposome function in the BAF A1-treated background demonstrated that BAF
322 A1 significantly inhibits clodronate liposome-mediated phagocyte depletion (**Fig. 5f**). The
323 observed phenotypes are strikingly similar to the *Tsp3A*-silenced background, as well as
324 the partial phenotypes associated with *PGAP6*, *Traf6*, and *TMEM147* RNAi which support
325 the hypothesis that these candidate genes have essential functions in phagolysosome
326 formation (**Fig. 5g**).

327 Together, these data support a model in which the phagocytic uptake of liposomes
328 involves *Traf6* and can be inhibited by CytoD treatment (**Fig. 6**). Additionally, the
329 knockdown of several genes, such as *Tsp3a*, *PGAP6*, and *TMEM147*, mimics the effect
330 of the BAF A1 inhibitor, indicating their role in further liposome processing and
331 phagolysosome formation. (**Fig. 6**). Although silencing of *GstD3* influenced clodronate

332 liposome function (**Fig. 3**), experiments examining liposome uptake and processing did
333 not yield phenotypes for *GstD3*, suggesting that *GstD3* contributes to the downstream
334 events that promote cell ablation (**Fig. 6**).

335 **Discussion**

336 Forward-genetic CRISPR knockout screens enable an unbiased interrogation of gene
337 function across a wide range of biological topics⁶². Although evidence has demonstrated
338 the utility of this forward-genetics approach from mammals^{63,64} to *Drosophila*^{19,22}, the
339 methodology had yet to be fully extended to other insect systems. We previously
340 developed the technology to enable pooled CRISPR knockout screening in mosquito
341 species and demonstrated its application through initial proof-of-principle studies²⁴. Here,
342 we performed the first genome-wide pooled CRISPR screens in *Anopheles* to identify
343 genes with essential roles in host fitness and provide new insights into the mechanisms
344 of clodronate liposome function in mosquitoes.

345 Our genome-wide CRISPR knockout fitness screen identified a total of 1280 genes using
346 a 5% FDR cutoff that are required for *Anopheles* Sua-5b cell growth, division, and/or
347 viability. Most of these genes (88%) are also essential in *Drosophila* S2R+ cells²¹, and
348 are highly enriched for genes encoding proteins involved in fundamental cell functions,
349 such as protein synthesis, RNA splicing, and protein degradation (**Fig. 1d**). In addition,
350 the list of *Drosophila* orthologs of the *Anopheles* essential genes includes 20% of genes
351 annotated in the GLAD resource as “mitochondrial,” 18% of genes annotated as
352 “metabolic,” 16% of genes annotated as “RNA-binding,” and 12% of genes annotated as
353 “transcription factors” (**Supplementary Table 2**). Furthermore, we found significant
354 overlap between the mosquito essential gene list and a list of ‘core essential genes’
355 identified in 17 CRISPR knockout screens in human cells⁴⁶. Altogether, these findings
356 support the quality of the gene dataset for mosquitoes and help to define a core set of
357 essential genes shared across metazoa.

358 Notably, the essential *Anopheles* genes identified in this screen might help lead to the
359 development of new approaches for mosquito control, such as targets for population
360 suppression strategies that aim to reduce or eliminate mosquito populations⁶⁵. For

361 example, an essential *Anopheles* gene could be genetically targeted to create a synthetic
362 gene-drive system capable of promoting lethality. In addition, the targeting of an essential
363 mosquito gene has the potential to enhance population replacement strategies relying on
364 CRISPR-Cas9¹⁷, homing endonuclease⁶⁶, Medea-like^{67,68}, or cleave and rescue^{69,70} as
365 a means for selection against non-replacement alleles in split-drive systems.

366 Clodronate liposomes have been widely used in studies of vertebrate immunology^{34,35},
367 and more recently in arthropod systems^{32,36,37}, to promote the targeted ablation of
368 phagocytic immune cell populations. While evidence suggests that clodronate-derived
369 metabolites act as ATP analogs to block mitochondrial ATP synthase activity and
370 consequently trigger apoptosis⁴⁷, the precise mechanisms of clodronate liposome uptake
371 and processing have not been adequately explored. Herein, the results of our genome-
372 wide CRISPR screen provide a comprehensive examination of clodronate liposome
373 function in *An. gambiae*. Using two screening methodologies, we identify a core set of 88
374 genes that are identified in one or both of our screens. This includes the enrichment of
375 genes involved in cellular metabolism, methyltransferase function, and autophagy that
376 bring new mechanistic insight into clodronate liposome function.

377 While the lack of RNAi and other limitations prevented downstream experiments for all
378 hits identified in the clodronate liposome screen, a further examination of several
379 identified genes infer additional subcellular components and pathways involved in
380 clodronate liposome function. For example, multiple hits are components of or involved
381 in the regulation of the serine/threonine-protein phosphatase 2A (PP2A) protein complex
382 involved in a variety of biological processes such as cell growth, differentiation, apoptosis,
383 and immune regulation⁷¹ PPME1, a methyl-esterase enzyme that acts directly on the
384 catalytic subunit by demethylation of the PP2A protein complex to cause its inactivation⁷².
385 Two other hits contribute to the regulation of the same protein complex: LCMT1
386 (AGAP008768), a methyl-transferase enzyme responsible for the methylation of PP2A at
387 the same site targeted by PPME1⁷³, and MASTL (AGAP001636) that acts by indirectly
388 promoting the inactivation of PP2A⁷⁴. With the PP2A protein phosphatase complex a
389 master regulator of several cellular functions, it could be important for clodronate induced
390 toxicity by mediating cytoskeleton rearrangements important for the uptake, trafficking, or

391 degradation of liposomes, to the downstream steps controlling its toxicity by activating the
392 Toll Like Receptor 3 (TLR3) cascade and apoptosis. Of note, both Pp2A-29B and MASTL
393 are essential genes in human cells (DepMap) and in *Anopheles* cells, yet are among the
394 most enriched targets in both clodronate screens. This suggests that, although the
395 knockout of these genes impacts cell fitness under "normal" conditions, their knockout
396 provides a growth advantage under clodronate selection, as the cells become less
397 sensitive to the drug compared to normal cells. In addition, multiple hits that correspond
398 to a serine/threonine-protein kinase signaling pathway involving RIOK3, ribosome
399 biogenesis and regulation of type I interferon (IFN)-dependent immune response are
400 represented in our clodronate liposome screen. In addition to RIOK3, two other hits
401 possibly belong in the same pathway, Oseg4 (AGAP011562), a TNF-stimulated gene
402 able to induce caspase 3-mediated apoptosis⁷⁵ and RPS17, a component of the 40S
403 ribosomal subunit that directly interacts with RIOK3 during ribosome biogenesis⁷⁶.
404 However, further experiments are required to establish exactly how these respective
405 PP2A and RIOK3 signaling components are involved in clodronate liposome function.

406 Through the use of pharmacological inhibitors that target endocytic pathways, we
407 demonstrate that the cellular uptake of clodronate liposomes is mediated by
408 phagocytosis, and not clathrin-mediated endocytosis, providing further support for the
409 specificity of clodronate liposomes to explicitly target phagocytic immune cells in both
410 arthropods³⁶ and mammals⁷⁷. In addition, one candidate identified in our clodronate
411 liposome CRISPR screen, Traf6, displayed notable defects in phagocytosis following
412 *Traf6*-silencing, supporting that Traf6 likely influences the uptake of clodronate liposomes.
413 However, as a RING-type ubiquitin ligase that interacts with several immune signaling
414 molecules^{78,79}, these effects are likely indirect. As a result, the phenotypes associated
415 with *Traf6*-silencing may be caused by the impaired production of downstream immune
416 effectors or defects in immune cell activation⁸⁰.

417 Additional microscopy, RNAi, and inhibitor experiments confirm that the formation of the
418 phagolysosome is a critical step in the processing of clodronate liposomes. Lysosomes
419 contain various hydrolytic enzymes that promote the breakdown of macromolecules for
420 degradation and cellular recycling⁸¹, thereby serving an essential role in the breakdown

421 of the liposome particle and the intracellular delivery of clodronate required to initiate cell
422 death. Taking advantage of the fluorescence of LP-DiO particles, we demonstrate the co-
423 localization of liposome particles with the lysosome, as well as the punctate and diffuse
424 patterns of DiO that enable the visualization of liposome processing. We demonstrate
425 that three candidate genes identified in our CRISPR screen, *Tsp3A*, *PGAP6*, and
426 *TMEM147*, have key roles in phagolysosome formation and validate these phenotypes in
427 liposome degradation through the use of the BAF A1 inhibitor to impair lysosome fusion.
428 While these data implicate *Tsp3A*, *PGAP6*, and *TMEM147* in the intracellular processing
429 of clodronate liposomes, their exact functions could not be fully resolved in our study.
430 Each of these genes are believed to localize to cell membranes and have been implicated
431 in immune cell function in orthologous systems⁸²⁻⁸⁴. While additional details of *Tsp3a* and
432 *TMEM147* function are limited, the human ortholog of *PGAP6* is a GPI-anchored
433 phospholipase with predicted localization to the lysosome^{83,85}, suggesting that *PGAP6*
434 could be essential to the breakdown of liposome particles and the subsequent release of
435 clodronate following phagolysosome formation. Similarly, other genes identified in our
436 screen such as *CLVS1* (AGAP005388) that are required for proper formation of late
437 endosomes and lysosomes⁸⁶, and *AGAP011017* which is of unknown function and
438 harbors a putative lipid binding domain (InterPro) similar to the Ganglioside GM2 activator
439 (GM2-AP) that acts as a lysosomal lipid transfer protein, further implicate lysosome fusion
440 as an important step in clodronate liposome function. However, one limitation of these
441 experiments was our inability to further define the role of *GstD3* in clodronate liposome
442 function, suggesting that *GstD3* acts downstream of liposome intracellular processing. As
443 a member of a large family of glutathione S-transferases involved in cellular detoxification
444 and insecticide resistance, *GstD3* may have roles in clodronate metabolism that ultimately
445 contribute to its ability to promote apoptosis and cell ablation.

446 A key step of clodronate toxicity is its incorporation into AMP molecules to form a non-
447 hydrolysable analog of ATP, the adenosine 5' β - γ -dichloromethylene triphosphate
448 (AppCCI2p), that has been shown to inhibit the mitochondrial translocase and putatively
449 induce apoptosis through mitochondrial depolarization. As a result, it has been proposed
450 that aminoacyl-tRNA synthetases could be responsible for the incorporation of clodronate

451 (a bisphosphonate analog of pyrophosphate, PPI) into AMP molecules by a reverse
452 reaction⁴⁷. However, the reaction in which PPI would be incorporated into ADP to
453 regenerate ATP is theoretically possible, but not favored due to thermodynamic and
454 kinetic constraints. In fact, the energy released from ATP hydrolysis and the rapid
455 degradation of PPI by pyrophosphatases ensure that the reverse process does not occur
456 naturally⁸⁷. As a result, aminoacyl-tRNA synthetases (aaRS) typically catalyze the
457 forward reaction of ATP hydrolysis to charge tRNA with an amino acid, producing AMP
458 and pyrophosphate (PPI)⁸⁸. However, the presence of a non-hydrolysable form of PPI,
459 such as clodronate, could hamper the stoichiometry of the reaction and one or multiple
460 enzymes that have PPI and AMP as byproducts, could potentially perform a reverse
461 reaction that incorporates clodronate into AMP molecules. While we did not find
462 aminoacyl-tRNA synthetases in our screen among the enriched hits, if this class of
463 enzymes are involved, a phenotype might not be observable as a result of the essential
464 nature of the aminoacyl-tRNA synthetase involved or because multiple aminoacyl-tRNA
465 synthetases could be catalyzing this reaction creating redundancy and masking the
466 phenotype from genetic enrichment. However, we did observe two nucleotide cyclases
467 among the enriched hits, ADCY5 (AGAP012805) and Gyc89Db (AGAP004564),
468 implicated respectively in the conversion of ATP/GTP to cAMP/cGMP and releasing PPI
469 in the process, yet are not known to catalyze the reverse reaction. Even though these
470 enzymes are not believed to contribute directly to the conversion of clodronate to toxic
471 AppCCl2p, the knockout of these enzymes may be partially protective because of the
472 decreased levels of cAMP/cGMP and the decreased activation of downstream pathways
473 driving cell toxicity. Both cyclic nucleotides are crucial second messengers regulating
474 diverse cellular functions like cellular immunity, autophagy and apoptosis⁸⁹.

475 While these results enhance our mechanistic understanding of mosquito essential genes
476 and clodronate liposome function, the candidate genes identified in our CRISPR screens
477 will undoubtedly inform a variety of other biological processes that influence mosquito
478 physiology and immune cell function. Based on comparative data in *Drosophila* and
479 human cell lines, we establish a core set of essential genes that can inform further studies
480 on other important mosquito vectors, such as those of the *Aedes* and *Culex* genus.

481 Moreover, the uptake and processing of clodronate liposomes is likely part of a common
482 biological process, such that the genes identified in our screen should provide additional
483 insight into the general mechanisms of phagocytosis and intracellular processing that may
484 inform aspects of host defense, autophagy, apoptosis, and immune cell maturation.
485 Altogether, the results from these initial genome-wide CRISPR screens provide a
486 foundation for additional studies in mosquito cells and *in vivo*, contributing to our further
487 understanding of mosquito biology and mosquito-borne diseases.

488 **Methods**

489 **Cell culturing**

490 The *Anopheles coluzzii* “screen-ready” (attP+ Cas9+) cell line Sua-5B-IE8-Act::Cas9-2A-
491 Neo¹ (CVCL_B3N3, Drosophila Genomics Resource Center, stock # 334) as previously
492 described²⁴. The cell line was cultured at 25°C in Schneider’s medium (Gibco), 1x
493 Penicillin-Streptomycin (Gibco) and 10% heat inactivated fetal bovine serum (Gibco) and
494 500 µg/ml of geneticin (G-418 sulfate, GoldBio).

495 **Genome-wide library design, and cloning**

496 sgRNAs targeting the whole genome of *Anopheles gambiae* (AgamP4.12) were selected
497 using CRISPR GuideXpress (<https://www.flyrnai.org/tools/fly2mosquito/web/>) and
498 following the previously described pipeline²⁴. Briefly, all computed sgRNAs were
499 retrieved, and the top seven sgRNAs per gene were selected based on the following
500 criteria: minimal OTE (off-target effect) score; maximum ML (machine learning efficiency)
501 score; and filtered to remove sgRNAs that match regions with SNPs in the *Anopheles*
502 *coluzzii* Sua-5B cell line genome sequence. In addition, sgRNA designs with the BbsI site
503 sequence were removed because BbsI is used for ligation-based cloning into the library
504 vector. The library includes 89,724 unique gene-targeting sgRNAs as well as control and
505 other sgRNAs, as detailed in **Supplementary Table 1**. The sgRNA sequences were
506 cloned into BbsI-digested pLib6.4B-Agam_695 (Accession # OL312683; Addgene #
507 176668) using the CloneEZ service (Genscript). Cloned vector was subsequently
508 reamplified with a theoretical coverage of <100 times in E. coli 10GF’ ELITE
509 Electrocompetent Cells (Lucigen) and grown in 500 mL of LB-Ampicillin media at 30°C
510 overnight and bacterial pellets were frozen at -80°C. Before transfection, plasmid DNA
511 was prepared from 50 mL pellets by midiprep (Zymo). Sequencing of the cloned plasmid
512 library confirmed the successful cloning of >98,3% (88159/89711) of designed sgRNAs,
513 detectable with at least one read/sgRNA (circa 94% of guides are detected with at least
514 10 reads/guide and about 1.7% were lost stochastically).

515 **Gene essentiality screen**

516 Sua-5B-IE8-Act::Cas9-2A-Neo cells in the log phase of growth were seeded at 35×10^6
517 cells per 100 mm dish in growth media containing antibiotics. They were transfected with
518 a plasmid mixture containing equimolar amounts of HSP70- Φ C31-Integrase plasmid
519 (pBS130) and sgRNA donor plasmid library (pLib6.4B-Agam_695) using Effectene
520 (Qiagen) according to the manufacturer's base protocol ("1:25"). We achieved a coverage
521 of ~ 244 cells/sgRNA by transfecting 735×10^6 cells [90208 sgRNAs $\times 244$ cells/sgRNA
522 $\times 0.03$ (RMCE efficiency) = 735×10^6] in 21 100-mm dishes. After 4 days, each dish was
523 expanded into 2 \times 150 cm dishes containing 5 mg/mL puromycin. Cells were cultured for
524 an additional 26 days with media changes and re-seeding every 4 days. Re-seeding at
525 each passage was maintained at a density above 1000 cells/sgRNA to ensure
526 representation of KO pool diversity. Cells were cultured up to 60 days (8 weeks) after
527 transfection. Following selection, genomic DNA was extracted from cell pellets containing
528 >1000 cells/sgRNA using the Quick-gDNA MaxiPrep kit (Zymo). Next, the genomic DNA
529 was barcoded and Illumina sequencing adapters were added via 2-step PCR
530 amplification. Amplicon sequencing was performed using a NextSeq500 at the
531 Biopolymers Facility at Harvard Medical School. Demultiplexing and trimming of barcode
532 labeling was performed using in-house scripts. sgRNAs with a low-read count (<10 reads
533 in the plasmid library) were removed from the readcount files. For identification of base
534 fitness genes the plasmid library vector readcounts from cells after 60 days post-
535 transfection were analyzed with MAGeCK MLE (version 0.5.6) to infer MLE Z-scores for
536 each gene.

537 To assess the significance of Z-score assignments in inferring true gene essentiality, Z-
538 score average from each replicate was calculated for each gene and plotted against
539 RNAseq expression values obtained from the Sua-5B cell line previously calculated⁹⁰.
540 False-discovery rate (FDR) was inferred from relationships between Z-score and gene
541 expression, as true fitness genes should be among the expressed genes, whereas the
542 identification of a fitness gene that is not expressed represents a false-discovery event.
543 Genes were binned every 5 genes, and the cumulative increase in false-discovery was
544 plotted as a function of Z-score to obtain the FDR. FDR ranking of essential genes
545 revealed 1280 essential genes with 95% confidence. Distribution by Gene Ontology terms

546 of major eukaryotic essential complex components for *Anopheles* within whole genome
547 Z-score distribution was displayed in **Figure 1d**.

548 **Ortholog mapping and comparison with essential genes in *Drosophila***

549 Mapping of *Anopheles* genes to *Drosophila* and to human ortholog was done using
550 DIOPT (v 9.0). Ortholog mapping was filtered based on DIOPT rank (only high or
551 moderate rank excluding low rank mapping) and the orthologs of the essential genes in
552 *Anopheles* were compared with the corresponding data from *Drosophila* or human
553 respectively. Comparisons with a comparable data set from a *Drosophila* CRISPR cell
554 screen were based on MLE Z values from a previous CRISPR screen in S2R+ cells (at
555 the same 5% FDR)²¹. Comparisons with human data were performed using the ‘core
556 essential’ genes identified from human cell lines⁴⁶. The essential genes in *Anopheles*
557 (**Supplementary Table 2**) are compared with *Drosophila* and human essential gene lists
558 in **Supplementary Table 3**.

559 **Gene set enrichment analysis**

560 To perform gene set enrichment analysis (GSEA), *Drosophila* orthologs mapped as
561 described above from mosquito genes that scored as essential (1280 genes) or ranked
562 within the first fifty hits in the two clodronate liposome screens (88 genes from Clodronate
563 A & B) were used as input for analysis with PANGEA³⁹. For essential gene orthologs,
564 gene set enrichment analysis was based on generic gene ontology (GO) slim biological
565 process (BP) terms⁴⁰; Gene List Annotation for *Drosophila* (GLAD) gene groups⁴¹, or
566 FlyBase phenotype annotations for classical mutations⁴², and the full sets of outputted
567 enrichment data from PANGEA are included in **Supplementary Table 2**. For clodronate
568 liposome screen hit analysis, the same three gene sets were used, and these were
569 supplemented by additional analysis using the *Drosophila* GO BP and FlyBase Gene
570 Group gene sets (**Supplementary Table 2**). The specific selections made at the
571 PANGEA user interface are indicated on the first row of the PANGEA analysis sheets
572 within **Supplementary Table 2** and **Supplementary Table 5**.

573 **Positive selection CRISPR screening with clodronate liposomes**

574 For the positive selection screen, 30 days post library transfection cells were selected in
575 media containing puromycin and 16 μ M liposome as a control or 8 μ M clodrosome. The
576 concentrations used in the screen were established for Sua-5B-IE8-Act::Cas9-2A-Neo
577 cells to be close to the IC50 for the clodrosome ($IC_{50}^{Clodrosome}=7.4 \mu\text{M}$) and negligible for
578 the liposome vehicle ($IC_{50}^{Liposome}=81.6 \mu\text{M}$), as established by assaying total ATP levels
579 (indirect readout of cell growth) during a 6-day treatment using the Cell Titer Glo assay
580 (Promega), as depicted in **Fig. 2A**. Cells were selected through three cycles of treatment.
581 Each cycle of treatment consisted of seeding the cells in media with liposome vehicle or
582 clodronate liposome, followed by media change and re-seeding two additional times.
583 Except in the case of the treatment “Clodronate B,” in which the cells were exposed to
584 selective media a single time for the first 4 days and then allowed to recover with normal
585 media before the next cycle, all the other treatments were performed by continuous
586 exposure to the selective media. The cells were re-seeded at a density above 1000
587 cells/sgRNA at each passage to ensure representation of KO pool diversity. Following
588 selection, genomic DNA extraction, barcoding, sequencing and analysis was performed
589 as detailed above. Readcount and data analysis, including enrichment analysis and
590 Robust Rank Aggregation score calculation, were performed using MaGeCK 0.5.7 and
591 scatter plots were visualized with Prism (v 10.1.0).

592 **Mosquito rearing**

593 *Anopheles gambiae* mosquitoes (Keele strain)⁹¹ were reared at 27°C and 80% relative
594 humidity, with a 14:10 hr light: dark photoperiod. Larvae were fed on commercialized fish
595 flakes (Tetra), while adults were maintained on a 10% sucrose solution and fed on
596 commercial sheep blood (Hemostat) for egg production.

597 **RNA isolation and gene expression analyses**

598 RNA isolation from whole adult mosquitoes was performed using TRIzol (Invitrogen,
599 Carlsland, CA) according to the manufacturer’s protocol. Two micrograms of total RNA
600 were used for first-strand synthesis using the LunaScript RT SuperMix Kit (NEB). Gene
601 expression was analyzed with quantitative real-time PCR (qPCR) using PowerUp
602 SYBRGreen Master Mix (Thermo Fisher Scientific), while results were analyzed using the

603 2^{-ΔCt} method and normalized against the internal reference, *rpS7*, as previously
604 described^{30,32,92}. All qPCR primers are listed in **Supplementary Table 6**.

605 **Timing experiments examining the uptake of fluorescent liposome particles**

606 To determine the approximate timing of liposome uptake *in vivo*, mosquitoes were
607 injected with 69 nl of Fluoroliposome-DiO (LP-DiO, Encapsula Nano Sciences) using a
608 1:50 dilution in 1X PBS. After injection, mosquitoes were incubated at 27°C for 1, 2, 6, 8,
609 or 12 hours, then were injected with a suspension containing 200 μM of Vibrant CM-Dil
610 (Thermo Fisher Scientific) and 2 mM of Hoechst 33342 (Thermo Fisher Scientific) to label
611 mosquito hemocytes. After an additional incubation of 30 min at 27°C to enable *in vivo*
612 staining, hemolymph was perfused from each mosquito using an anticoagulant buffer of
613 60% v/v Schneider's Insect medium, 10% v/v fetal bovine serum (FBS), and 30% v/v
614 citrate buffer (98 mM NaOH, 186 mM NaCl, 1.7 mM EDTA, and 41 mM citric acid; buffer
615 pH 4.5) as previously described^{30–33,51}. Hemolymph perfusions were placed directly on
616 multi-well microscopic slides for downstream analysis by microscopy. Cells were allowed
617 to adhere for 20 min and fixed with 4% paraformaldehyde (PFA) for 10 min, followed by
618 five washing steps with 1X PBS. Samples were observed under a Zeiss fluorescent
619 microscope to calculate the percentage of hemocytes (of total) taking up the fluorescent
620 LP-DiO particles.

621 **Phagocyte depletion with clodronate liposomes**

622 Naïve mosquitoes were injected with either clodronate (CLD) or control (LP) liposomes
623 (Encapsula Nano Sciences) to deplete phagocytic immune cell populations in *Anopheles*
624 *gambiae* as previously described^{32,33,51}. Based on the demonstrated IC₅₀ of clodronate
625 liposomes *in vitro* as part of this study, liposomes were diluted to a similar concentration
626 using a 1:50 dilution in 1X PBS for all *in vivo* studies herein. Previous studies were
627 performed using a more concentrated 1:5 dilution^{32,33,51}. Final concentrations of
628 clodronate liposomes were calculated based on a hemolymph volume of ~2 μl⁹³. To
629 determine the approximate time needed for phagocyte depletion, mosquitoes were
630 injected with either 69nl of CLD or LP, and then incubated at 27°C for 6, 8, 12, or 24
631 hours. Whole mosquito samples were then processed for RNA isolation and cDNA

632 synthesis as described above. The expression levels of *Eater* and *Nimrod B2* were used
633 as a proxy to demonstrate phagocyte (granulocyte) depletion^{32,33,51}.

634 **dsRNA synthesis and gene-silencing**

635 Candidate genes identified in the genome-wide CRISPR screen were validated using
636 RNAi-mediated gene silencing to confirm their functional roles in the mode of clodronate
637 action. T7 primers specific to each gene (**Supplementary Table 6**) were used to amplify
638 DNA templates from whole female mosquito cDNA samples to synthesize long dsRNAs
639 using the MEGAscript RNAi kit (Thermo Fisher Scientific). Following synthesis, the
640 concentration of dsRNAs was adjusted to 3 µg/µl. Adult female mosquitoes (3-5 days old)
641 were cold anesthetized and injected with 69 nl of dsRNA targeting each candidate gene.
642 For each experiment, mosquitoes were also injected with dsRNA targeting GFP as a
643 negative control. All injections were performed using Nanoject III (Drummond Scientific).
644 Gene-silencing efficiency was evaluated by qPCR 2 days post-injection. All experiments
645 were performed in triplicate.

646 **Hemolymph perfusion and hemocyte counting**

647 Hemolymph was perfused in adult female *An. gambiae* through the intrathoracic injection
648 of an anticoagulant solution and collection of the perfusate through a small incision in the
649 abdomen as previously described^{30,31}. To determine total hemocyte numbers, the
650 collected perfusion from an individual mosquito was added to a disposable Neubauer
651 Improved hemocytometer slide (iNCYTO C-Chip DHC-N01) as previously^{29,30,94}.

652 **Malaria parasite infection**

653 Infections with the rodent malaria model, *Plasmodium berghei*, were performed by first
654 infecting Swiss Webster mice (Charles River) with *P. berghei*-mCherry⁹⁵ parasites as
655 previously described^{30,92}. Mosquito infections were performed by allowing mosquitoes to
656 feed on anesthetized *P. berghei*-infected mouse. Following feeding, fully engorged
657 mosquitoes were selected by cold-sorting, then were placed at 19°C. Oocyst numbers
658 were evaluated by fluorescence microscopy in dissected midguts at 10 days post-
659 infection.

660 **Use of inhibitors to examine liposome uptake**

661 To examine the mechanisms of liposome uptake by mosquito hemocytes, mosquitoes
662 were treated with 200 μ M Cytochalasin D (CytoD, Sigma) to inhibit phagocytosis^{55–58} or
663 25 μ g/ml Chlorpromazine hydrochloride (CPZ, MP Biomedical) to impair clathrin-
664 mediated endocytosis^{52–54}. Mosquitoes injected with 10% DMSO in 1X PBS were used
665 as negative controls. At 6h post-injection, mosquitoes were injected with a 1:50 dilution
666 of Fluoroliposome-DiO (LP-DiO) in 1X PBS, and then incubated for 8h at 27°C. Following
667 injection with 2 mM Hoechst 33342 to counterstain nuclei, hemolymph was perfused from
668 individual mosquito samples and then observed using a fluorescent microscope to
669 determine the proportions of hemocytes containing fluorescent liposome particles.

670 Additional experiments were performed to confirm the effects of CytoD on clodronate
671 liposome uptake. Mosquitoes were first injected with 200 μ M CytoD or 10% DMSO in 1X
672 PBS and allowed to recover for 6h at 27°C, then followed by injection with control or
673 clodronate liposomes (diluted at 1:50) and incubated at 27°C for 8 hours. The influence
674 of CytoD on clodronate liposome function and resulting phagocyte depletion was
675 evaluated by proxy through the analysis of *Nimrod B2* expression via qPCR^{32,33,51}.

676 **Phagocytosis assays**

677 The effects of candidate genes or inhibitors on phagocytosis were evaluated by injecting
678 adult female mosquitoes with 69 nl of 2% of green fluorescent FluoSpheres (1 μ m;
679 Thermo Fisher Scientific) similar to previous studies^{30,32,96}. In addition to the beads,
680 mosquitoes were concurrently injected with 100 μ M Vibrant CM-Dil and 2 mM of Hoechst
681 33342 in 1X PBS to counterstain hemocytes, then allowed to recover for 30 min at 27°C.
682 The effects of gene-silencing on phagocytosis were examined approximately 48h after
683 injection with dsRNAs, while the effects of the inhibitor Cytochalasin D were analyzed at
684 6h post-injection to serve as a positive control to impair phagocytosis⁵⁷. For each
685 experiment, hemolymph was perfused from individual mosquitoes using an anticoagulant
686 buffer and placed on multi-well microscope slides. Hemocytes were allowed to adhere for
687 20 min and fixed with 4% PFA. Following five washing steps, samples were mounted with
688 Aqua Poly/Mount (Polysciences) and observed under a fluorescent microscope to

689 determine the percentage of phagocytic cells. Approximately 50 hemocytes were counted
690 per individual mosquito, with data collected from two or more replicates (n=16+ mosquito
691 samples).

692 **Use of gene-silencing to examine liposome uptake and processing**

693 To determine the roles of candidate genes on liposome uptake and processing, candidate
694 genes were first silenced by the injection of dsRNA in naive adult female mosquitoes.
695 Two days post-injection, gene-silenced mosquitoes were injected with a 1:50 dilution of
696 Fluoroliposome-DiO in 1X PBS. Following incubation for 8 hours, phenotypes were
697 evaluated in individual mosquitoes as the percentage of hemocytes containing liposome
698 particles (LP-DiO⁺) to evaluate liposome uptake, or as diffused patterns of DiO (DiO⁺) in
699 the cytosol that support liposome processing and degradation.

700 **Immunofluorescence of cellular localization**

701 To visualize the co-localization of liposome particles with the lysosome, mosquitoes were
702 perfused with an anticoagulant buffer at 8h post-injection with a 1:50 dilution of LP-DiO.
703 Hemocytes were allowed to adhere for 30 min without fixation, and then incubated with
704 the lysosome-specific dye, LysoView 594 (Biotium), using a 1:500 dilution in 1X PBS for
705 1 hour. Samples were mounted with ProLongDiamond AntiFade Mountant with DAPI (Life
706 Technologies) and immediately observed using fluorescence microscopy (Zeiss Axio
707 Imager.M2).

708 **Use of inhibitors to impair lysosome acidification**

709 To investigate the involvement of lysosome function in regulating the processing of
710 clodronate-liposomes, mosquitoes were treated with 25 μ M of Bafilomycin A1 (BafA1;
711 Cayman), a proton pump V-ATPase inhibitor, or 10% DMSO in 1X PBS. Mosquitoes were
712 incubated for 16h at 27°C as previously described⁹⁷, then injected with Fluoroliposome-
713 DiO using a 1:50 dilution in 1X PBS. The number of hemocytes displaying intact liposome
714 particles (LP-DiO⁺) or diffused patterns of DiO (DiO⁺) in the cytosol was determined by
715 immunofluorescence. To examine the effects of BafA1 on clodronate function,
716 mosquitoes were injected with clodronate or control liposomes at 1:50 dilution in 1X PBS

717 following treatment with Baf A1. At 8h post-injection, phagocyte depletion was evaluated
718 by proxy through *Nimrod B2* expression via qPCR^{32,33,51}.

719 **Acknowledgments**

720 We would like to thank Ian Schneider for kindly providing the cytochalasin D inhibitor.
721 Work at the Drosophila Research & Screening Center-Biomedical Technology Research
722 Resource (DRSC-BTRR) was supported by NIH NIGMS P41 GM132087 to NP and SEM.
723 Additional support was provided by NIH R21 AI166857 to RCS, while DRH is supported
724 by the National Science Foundation Graduate Research Fellowship Program under Grant
725 No. 2336877. NP is an Investigator of the Howard Hughes Medical Institute. This article
726 is subject to HHMI's Open Access to Publications policy. HHMI lab heads have previously
727 granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to
728 HHMI in their research articles. Pursuant to those licenses, the author-accepted
729 manuscript of this article can be made freely available under a CC BY 4.0 license
730 immediately upon publication.

731 References

- 732 1. World Health Organization. *Global Brief on Vector-Borne Diseases*. (World Health
733 Organization, 2022).
- 734 2. Athni, T. S. *et al.* The influence of vector-borne disease on human history: socio-
735 ecological mechanisms. *Ecol. Lett.* **24**, 829–846 (2021).
- 736 3. Bhatt, S. *et al.* The global distribution and burden of dengue. *Nature* **496**, 504–507
737 (2013).
- 738 4. World Health Organization. *World Malaria Report 2023*. (World Health Organization,
739 2023).
- 740 5. Clemons, A. *et al.* *Aedes aegypti*: an emerging model for vector mosquito
741 development. *Cold Spring Harb. Protoc.* **2010**, db.emo141 (2010).
- 742 6. Kato, Y. & Sakuma, C. Extrinsic and intrinsic regulation of blood feeding in
743 mosquitoes. *Curr Opin Insect Sci* 101221 (2024).
- 744 7. Parres-Mercader, M., Pance, A. & Gómez-Díaz, E. Novel systems to study vector-
745 pathogen interactions in malaria. *Front. Cell. Infect. Microbiol.* **13**, 1146030 (2023).
- 746 8. Bier, E. Gene drives gaining speed. *Nat. Rev. Genet.* **23**, 5–22 (2022).
- 747 9. Scott, J. G. *et al.* Towards the elements of successful insect RNAi. *J. Insect Physiol.*
748 **59**, 1212–1221 (2013).
- 749 10. Coates, C. J., Jasinskiene, N., Miyashiro, L. & James, A. a. Mariner transposition and
750 transformation of the yellow fever mosquito, *Aedes aegypti*. *Proc. Natl. Acad. Sci. U.*
751 *S. A.* **95**, 3748–3751 (1998).
- 752 11. Grossman, G. L. *et al.* Germline transformation of the malaria vector, *Anopheles*
753 *gambiae*, with the piggyBac transposable element. *Insect Mol. Biol.* **10**, 597–604
754 (2001).
- 755 12. Aryan, A., Anderson, M. a. E., Myles, K. M. & Adelman, Z. N. TALEN-Based Gene
756 Disruption in the Dengue Vector *Aedes aegypti*. *PLoS One* **8**, (2013).
- 757 13. Smidler, A. L., Terenzi, O., Soichot, J., Levashina, E. a. & Marois, E. Targeted
758 Mutagenesis in the Malaria Mosquito Using TALE Nucleases. *PLoS One* **8**, 1–9
759 (2013).
- 760 14. Kistler, K. E., Vosshall, L. B. & Matthews, B. J. Genome engineering with CRISPR-
761 Cas9 in the mosquito *aedes aegypti*. *Cell Rep.* **11**, 51–60 (2015).
- 762 15. Gantz, V. M. *et al.* Highly efficient Cas9-mediated gene drive for population
763 modification of the malaria vector mosquito *Anopheles stephensi*. *Proceedings of the*
764 *National Academy of Sciences* 201521077 (2015).
- 765 16. Matthews, B. J. & Vosshall, L. B. How to turn an organism into a model organism in
766 10 ‘easy’ steps. *Journal of Experimental Biology* **223**, jeb218198 (2020).
- 767 17. Hammond, A. *et al.* A CRISPR-Cas9 gene drive system targeting female
768 reproduction in the malaria mosquito vector *Anopheles gambiae*. *Nat. Biotechnol.* **34**,
769 1–8 (2015).

- 770 18. Quinn, C., Anthousi, A., Wondji, C. & Nolan, T. CRISPR-mediated knock-in of
771 transgenes into the malaria vector *Anopheles funestus*. *G3* **11**, (2021).
- 772 19. Viswanatha, R., Li, Z., Hu, Y. & Perrimon, N. Pooled genome-wide CRISPR
773 screening for basal and context-specific fitness gene essentiality in cells. *Elife* **7**,
774 (2018).
- 775 20. Viswanatha, R. *et al.* Pooled CRISPR screens in *Drosophila* cells. *Curr. Protoc. Mol.*
776 *Biol.* **129**, e111 (2019).
- 777 21. Viswanatha, R., Entwisle, S., Hu, Y., Mohr, S. E. & Perrimon, N. Higher resolution
778 pooled genome-wide CRISPR knockout screening in *Drosophila* cells using
779 integration and anti-CRISPR (IntAC). *bioRxiv* (2024)
780 doi:10.1101/2024.09.19.613976.
- 781 22. Okamoto, N. *et al.* A Membrane Transporter Is Required for Steroid Hormone Uptake
782 in *Drosophila*. *Dev. Cell* **1–12** (2018).
- 783 23. Xu, Y. *et al.* CRISPR screens in *Drosophila* cells identify *Vsg* as a Tc toxin receptor.
784 *Nature* **610**, 349–355 (2022).
- 785 24. Viswanatha, R. *et al.* Bioinformatic and cell-based tools for pooled CRISPR knockout
786 screening in mosquitos. *Nat. Commun.* **12**, 6825 (2021).
- 787 25. Foley, E. & O’Farrell, P. H. Functional dissection of an innate immune response by
788 a genome-wide RNAi screen. *PLoS Biol.* **2**, (2004).
- 789 26. Hillyer, J. F. & Strand, M. R. Mosquito hemocyte-mediated immune responses.
790 *Current Opinion in Insect Science* **3**, 14–21 (2014).
- 791 27. Leite, T. H. J. F., Ferreira, Á. G. A., Imler, J.-L. & Marques, J. T. Distinct Roles of
792 Hemocytes at Different Stages of Infection by Dengue and Zika Viruses in *Aedes*
793 *aegypti* Mosquitoes. *Front. Immunol.* **12**, 660873 (2021).
- 794 28. Hall, D. R. *et al.* Mosquito immune cells enhance dengue and Zika virus
795 dissemination in *Aedes aegypti*. *bioRxiv* (2024) doi:10.1101/2024.04.03.587950.
- 796 29. Ramirez, J. L. *et al.* The role of hemocytes in *Anopheles gambiae* antiplasmodial
797 immunity. *J. Innate Immun.* **6**, 119–128 (2014).
- 798 30. Smith, R. C., Barillas-Mury, C. & Jacobs-Lorena, M. Hemocyte differentiation
799 mediates the mosquito late-phase immune response against *Plasmodium* in
800 *Anopheles gambiae*. *Proceedings of the National Academy of Sciences* **112**, E3412–
801 20 (2015).
- 802 31. Smith, R. C. *et al.* Molecular profiling of phagocytic immune cells in *Anopheles*
803 *gambiae* reveals integral roles for hemocytes in mosquito innate immunity. *Mol. Cell.*
804 *Proteomics* **15**, 3373–3387 (2016).
- 805 32. Kwon, H. & Smith, R. C. Chemical depletion of phagocytic immune cells in *Anopheles*
806 *gambiae* reveals dual roles of mosquito hemocytes in anti-*Plasmodium* immunity.
807 *Proc. Natl. Acad. Sci. U. S. A.* **116**, 14119–14128 (2019).
- 808 33. Kwon, H., Hall, D. R. & Smith, R. C. Prostaglandin E2 Signaling Mediates Oenocytoid
809 Immune Cell Function and Lysis, Limiting Bacteria and *Plasmodium* Oocyst Survival

- 810 in *Anopheles gambiae*. *Front. Immunol.* **12**, 680020 (2021).
- 811 34. van Rooijen, N. & van Kesteren-Hendrikx, E. Clodronate liposomes: perspectives in
812 research and therapeutics. *J. Liposome Res.* **12**, 81–94 (2002).
- 813 35. van Rooijen, N. & Hendrikx, E. Liposomes for Specific Depletion of Macrophages
814 from Organs and Tissues. in *Liposomes, Methods in Molecular Biology* vol. 605 189–
815 203 (2010).
- 816 36. Ramesh Kumar, J., Smith, J. P., Kwon, H. & Smith, R. C. Use of Clodronate
817 Liposomes to Deplete Phagocytic Immune Cells in *Drosophila melanogaster* and
818 *Aedes aegypti*. *Front Cell Dev Biol* **9**, 627976 (2021).
- 819 37. Adegoke, A., Ribeiro, J. M. C., Brown, S., Smith, R. C. & Karim, S. Rickettsia parkeri
820 hijacks tick hemocytes to manipulate cellular and humoral transcriptional responses.
821 *Front. Immunol.* **14**, 1094326 (2023).
- 822 38. Li, W. *et al.* MAGeCK enables robust identification of essential genes from genome-
823 scale CRISPR/Cas9 knockout screens. *Genome Biol.* **15**, 554 (2014).
- 824 39. Hu, Y. *et al.* PANGEA: a new gene set enrichment tool for *Drosophila* and common
825 research organisms. *Nucleic Acids Res.* **51**, W419–W426 (2023).
- 826 40. Gene Ontology Consortium *et al.* The Gene Ontology knowledgebase in 2023.
827 *Genetics* **224**, (2023).
- 828 41. Hu, Y., Comjean, A., Perkins, L. A., Perrimon, N. & Mohr, S. E. GLAD: An online
829 database of gene list annotation for *Drosophila*. *J. Genomics* **3**, 75–81 (2015).
- 830 42. Öztürk-Çolak, A. *et al.* FlyBase: updates to the *Drosophila* genes and genomes
831 database. *Genetics* **227**, (2024).
- 832 43. Mansfield, J. H., Wilhelm, J. E. & Hazelrigg, T. Ypsilon Schachtel, a *Drosophila* Y-
833 box protein, acts antagonistically to Orb in the oskar mRNA localization and
834 translation pathway. *Development* **129**, 197–209 (2002).
- 835 44. Fossett, N., Hyman, K., Gajewski, K., Orkin, S. H. & Schulz, R. a. Combinatorial
836 interactions of serpent, lozenge, and U-shaped regulate crystal cell lineage
837 commitment during *Drosophila* hematopoiesis. *Proc. Natl. Acad. Sci. U. S. A.* **100**,
838 11451–11456 (2003).
- 839 45. Waltzer, L., Ferjoux, G., Bataillé, L. & Haenlin, M. Cooperation between the GATA
840 and RUNX factors Serpent and Lozenge during *Drosophila* hematopoiesis. *EMBO J.*
841 **22**, 6516–6525 (2003).
- 842 46. Hart, T. *et al.* Evaluation and design of genome-wide CRISPR/SpCas9 knockout
843 screens. *G3* **7**, 2719–2727 (2017).
- 844 47. Mönkkönen, H. *et al.* The cellular uptake and metabolism of clodronate in RAW 264
845 macrophages. *Pharm. Res.* **18**, 1550–1555 (2001).
- 846 48. Giannoni, F. *et al.* Nuclear factors bind to a conserved DNA element that modulates
847 transcription of *Anopheles gambiae* trypsin genes. *J. Biol. Chem.* **276**, 700–707
848 (2001).
- 849 49. Alliance of Genome Resources Consortium. Updates to the Alliance of Genome


- 850 Resources central infrastructure. *Genetics* **227**, (2024).
- 851 50. Attrill, H. *et al.* FlyBase: establishing a Gene Group resource for *Drosophila*
852 *melanogaster*. *Nucleic Acids Res.* **44**, D786–92 (2016).
- 853 51. Kwon, H., Mohammed, M., Franzén, O., Ankarklev, J. & Smith, R. C. Single-cell
854 analysis of mosquito hemocytes identifies signatures of immune cell subtypes and
855 cell differentiation. *Elife* **10**, (2021).
- 856 52. Acosta, E. G., Castilla, V. & Damonte, E. B. Functional entry of dengue virus into
857 *Aedes albopictus* mosquito cells is dependent on clathrin-mediated endocytosis. *J.*
858 *Gen. Virol.* **89**, 474–484 (2008).
- 859 53. Vercauteren, D. *et al.* The use of inhibitors to study endocytic pathways of gene
860 carriers: optimization and pitfalls. *Mol. Ther.* **18**, 561–569 (2010).
- 861 54. Wang, L. H., Rothberg, K. G. & Anderson, R. G. Mis-assembly of clathrin lattices on
862 endosomes reveals a regulatory switch for coated pit formation. *J. Cell Biol.* **123**,
863 1107–1117 (1993).
- 864 55. Goddette, D. W. & Frieden, C. Actin polymerization. The mechanism of action of
865 cytochalasin D. *J. Biol. Chem.* **261**, 15974–15980 (1986).
- 866 56. Newman, S. L., Bucher, C., Rhodes, J. & Bullock, W. E. Phagocytosis of *Histoplasma*
867 *capsulatum* yeasts and microconidia by human cultured macrophages and alveolar
868 macrophages. Cellular cytoskeleton requirement for attachment and ingestion. *J.*
869 *Clin. Invest.* **85**, 223–230 (1 1990).
- 870 57. Kapetanovic, R. *et al.* Contribution of phagocytosis and intracellular sensing for
871 cytokine production by *Staphylococcus aureus*-activated macrophages. *Infect.*
872 *Immun.* **75**, 830–837 (2007).
- 873 58. Schulz, D., Severin, Y., Zanutelli, V. R. T. & Bodenmiller, B. In-Depth
874 Characterization of Monocyte-Derived Macrophages using a Mass Cytometry-Based
875 Phagocytosis Assay. *Sci. Rep.* **9**, 1925 (2019).
- 876 59. Uribe-Querol, E. & Rosales, C. Phagocytosis: Our Current Understanding of a
877 Universal Biological Process. *Front. Immunol.* **11**, 1066 (2020).
- 878 60. Gordon, S. Phagocytosis: An Immunobiologic Process. *Immunity* **44**, 463–475
879 (2016).
- 880 61. Lee, H.-J., Woo, Y., Hahn, T.-W., Jung, Y. M. & Jung, Y.-J. Formation and Maturation
881 of the Phagosome: A Key Mechanism in Innate Immunity against Intracellular
882 Bacterial Infection. *Microorganisms* **8**, (2020).
- 883 62. Bock, C. *et al.* High-content CRISPR screening. *Nat Rev Methods Primers* **2**, (2022).
- 884 63. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells
885 using the CRISPR-Cas9 system. *Science* **343**, 80–84 (2014).
- 886 64. Chen, S. *et al.* Genome-wide CRISPR screen in a mouse model of tumor growth and
887 metastasis. *Cell* **160**, 1246–1260 (2015).
- 888
- 889 65. Wang, G.-H. *et al.* Combating mosquito-borne diseases using genetic control

- 890 technologies. *Nat. Commun.* **12**, 4388 (2021).
- 891 66. Windbichler, N. *et al.* A synthetic homing endonuclease-based gene drive system in
892 the human malaria mosquito. *Nature* **473**, 212–215 (2011).
- 893 67. Chen, C.-H. *et al.* A Synthetic Maternal-Effect Selfish Genetic Element Drives
894 Population Replacement in *Drosophila*. *Science* **316**, 597–600 (2007).
- 895 68. Akbari, O. S. *et al.* Novel synthetic Medea selfish genetic elements drive population
896 replacement in *Drosophila*; a theoretical exploration of Medea-dependent population
897 suppression. *ACS Synth. Biol.* **3**, 915–928 (2014).
- 898 69. Oberhofer, G., Ivy, T. & Hay, B. A. Cleave and Rescue, a novel selfish genetic
899 element and general strategy for gene drive. *Proc. Natl. Acad. Sci. U. S. A.* **116**,
900 6250–6259 (2019).
- 901 70. Oberhofer, G., Ivy, T. & Hay, B. A. Split versions of Cleave and Rescue selfish
902 genetic elements for measured self limiting gene drive. *PLoS Genet.* **17**, e1009385
903 (2021).
- 904 71. Jeong, B.-C. *et al.* Cryo-EM structure of the Hippo signaling integrator human
905 STRIPAK. *Nat. Struct. Mol. Biol.* **28**, 290–299 (2021).
- 906 72. Ogris, E. *et al.* A protein phosphatase methylesterase (PME-1) is one of several
907 novel proteins stably associating with two inactive mutants of protein phosphatase
908 2A. *J. Biol. Chem.* **274**, 14382–14391 (1999).
- 909 73. De Baere, I. *et al.* Purification of porcine brain protein phosphatase 2A leucine
910 carboxyl methyltransferase and cloning of the human homologue. *Biochemistry* **38**,
911 16539–16547 (1999).
- 912 74. Vigneron, S. *et al.* Greatwall maintains mitosis through regulation of PP2A. *EMBO J.*
913 **28**, 2786–2793 (2009).
- 914 75. Feng, G.-G. *et al.* Naofen, a novel WD40-repeat protein, mediates spontaneous and
915 tumor necrosis factor-induced apoptosis. *Biochem. Biophys. Res. Commun.* **394**,
916 153–157 (2010).
- 917 76. Cho, N. H. *et al.* OpenCell: Endogenous tagging for the cartography of human cellular
918 organization. *Science* **375**, eabi6983 (2022).
- 919 77. Van Rooijen, N. & Sanders, A. Liposome mediated depletion of macrophages:
920 mechanism of action, preparation of liposomes and applications. *J. Immunol.*
921 *Methods* **174**, 83–93 (1994).
- 922 78. Fu, T.-M., Shen, C., Li, Q., Zhang, P. & Wu, H. Mechanism of ubiquitin transfer
923 promoted by TRAF6. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1783–1788 (2018).
- 924 79. Dainichi, T., Matsumoto, R., Mostafa, A. & Kabashima, K. Immune control by TRAF6-
925 mediated pathways of epithelial cells in the EIME (epithelial immune
926 microenvironment). *Front. Immunol.* **10**, 1107 (2019).
- 927 80. Walsh, M. C., Lee, J. & Choi, Y. Tumor necrosis factor receptor- associated factor 6
928 (TRAF6) regulation of development, function, and homeostasis of the immune
929 system. *Immunol. Rev.* **266**, 72–92 (2015).

- 930 81. Trivedi, P. C., Bartlett, J. J. & Pulinilkunnil, T. Lysosomal biology and function:
931 Modern view of cellular debris bin. *Cells* **9**, 1131 (2020).
- 932 82. Navarro-Hernandez, I. C. *et al.* Tetraspanin 33 (TSPAN33) regulates endocytosis
933 and migration of human B lymphocytes by affecting the tension of the plasma
934 membrane. *FEBS J.* **287**, 3449–3471 (2020).
- 935 83. Lee, G.-H. *et al.* A GPI processing phospholipase A2, PGAP6, modulates Nodal
936 signaling in embryos by shedding CRIPTO. *J. Cell Biol.* **215**, 705–718 (2016).
- 937 84. Cheng, S. *et al.* TMEM147 correlates with immune infiltration and serve as a potential
938 prognostic biomarker in hepatocellular carcinoma. *Anal. Cell. Pathol.* **2023**, 4413049
939 (2023).
- 940 85. Lee, G.-H. *et al.* PGAP6, a GPI-specific phospholipase A2, has narrow substrate
941 specificity against GPI-anchored proteins. *J. Biol. Chem.* **295**, 14501–14509 (2020).
- 942 86. Katoh, Y. *et al.* The clavesin family, neuron-specific lipid- and clathrin-binding Sec14
943 proteins regulating lysosomal morphology. *J. Biol. Chem.* **284**, 27646–27654 (2009).
- 944 87. Ghosh, P. K., Ghosh, A. K. & Biswas, N. M. Effect of Cadmium on 17 β -
945 Hydroxysteroid Dehydrogenase in Toad Testis. *Andrologia* **19**, 143–147 (1987).
- 946 88. Pang, L., Weeks, S. D. & Van Aerschot, A. Aminoacyl-tRNA synthetases as valuable
947 targets for antimicrobial drug discovery. *Int. J. Mol. Sci.* **22**, 1750 (2021).
- 948 89. Ladilov, Y. & Appukuttan, A. Role of soluble adenylyl cyclase in cell death and
949 growth. *Biochim. Biophys. Acta* **1842**, 2646–2655 (2014).
- 950 90. Viswanatha, R., Li, Z., Hu, Y. & Perrimon, N. Pooled genome-wide CRISPR
951 screening for basal and context-specific fitness gene essentiality in *Drosophila* cells.
952 *Elife* **7**, (2018).
- 953 91. Ranford-Cartwright, L. C. *et al.* Characterisation of Species and Diversity of
954 *Anopheles gambiae* Keele Colony. *PLoS One* **11**, e0168999 (2016).
- 955 92. Smith, R. C., Eappen, A. G., Radtke, A. J. & Jacobs-Lorena, M. Regulation of Anti-
956 Plasmodium Immunity by a LITAF-like Transcription Factor in the Malaria Vector
957 *Anopheles gambiae*. *PLoS Pathog.* **8**, e1002965 (2012).
- 958 93. Shapiro, A. B. *et al.* Juvenile hormone and juvenile hormone esterase in adult
959 females of the mosquito *Aedes aegypti*. *J. Insect Physiol.* **32**, 867–877 (1986).
- 960 94. Rodrigues, J., Brayner, F. A., Alves, L. C., Dixit, R. & Barillas-Mury, C. Hemocyte
961 differentiation mediates innate immune memory in *Anopheles gambiae* mosquitoes.
962 *Science* **329**, 1353–1355 (2010).
- 963 95. Graewe, S., Retzlaff, S., Struck, N., Janse, C. J. & Heussler, V. T. Going live: A
964 comparative analysis of the suitability of the RFP derivatives RedStar, mCherry and
965 tdTomato for intravital and in vitro live imaging of Plasmodium parasites. *Biotechnol.*
966 *J.* **4**, 895–902 (2009).
- 967 96. Reynolds, R. A., Kwon, H. & Smith, R. C. 20-Hydroxycydysone Primes Innate
968 Immune Responses That Limit Bacterial and Malarial Parasite Survival in *Anopheles*
969 *gambiae*. *mSphere* **5**, (2020).

- 970 97. Kang, S., Shields, A. R., Jupatanakul, N. & Dimopoulos, G. Suppressing dengue-2
971 infection by chemical inhibition of *Aedes aegypti* host factors. *PLoS Negl. Trop. Dis.*
972 **8**, e3084 (2014).


973 Figures



974


975 **Fig. 1. Genome-wide CRISPR knockout screen reveals genes required for fitness**
 976 **in *Anopheles* Sua-5B cells.** (a) Schematic for gene essentiality CRISPR screen.
 977 CRISPR GuideXpress was used to design a whole-genome sgRNA library targeting
 978 protein-coding and non-coding *Anopheles gambiae* genes. The library was cloned into
 979 the pLib6.4B_695 vector and delivered to Sua-5B-IE8-Act::Cas9-2A-Neo via Φ C31
 980 recombination-mediated cassette exchange to yield a pool of knockout cells. During
 981 outgrowth, cells that received sgRNAs targeting essential genes will “drop out” of the KO
 982 pool. The relative abundance of each sgRNA in the KO outgrowth pool of cells was
 983 compared to the plasmid library by NGS followed by MAGeCK MLE analysis. (b)
 984 Genome-wide library coverage. The starting library design includes 90,208 sgRNAs
 985 (88,763 unique sgRNAs) targeting 93% of *Anopheles* genes, with 7 sgRNAs per gene
 986 coverage for ~96% of these genes. (c) Data analysis. MAGeCK MLE was used to analyze
 987 gene essentiality. Using the relationship between gene expression and Z-score rank, we
 988 can identify ~1,300 essential genes with 95% confidence (FDR=0.05). Their distribution

989 by category is shown in (d): colored data points within the Z-score whole genome
990 distribution (grey dots) highlight genes belonging to each essential category by Gene
991 Ontology term (Cytoplasmic Ribosome KEGG:aga030008; Mitochondrial Ribosome
992 GO:0098798,0005763; Spliceosome KEGG:aga03040; Proteasome KEGG:aga03050);
993 red line intercept of *x axis* represents Z-score essentiality threshold at FDR=0.05. (e)
994 Comparison of essential genes identified in *Anopheles* and *Drosophila*. To compare gene
995 lists between the two species, all *Anopheles* genes were mapped to corresponding
996 *Drosophila* orthologs, then their respective essentiality scores from cell pooled CRISPR
997 knockout screens were plotted. Colored inbox within the plot highlights *Anopheles*
998 essential genes with Z-scores within FDR=0.05; fitted linear trendline and R^2 squared
999 value are displayed to highlight the correlation trend between datasets; *yps* single
1000 datapoint was darkened to enhance its visibility.



1001
 1002 **Fig. 2. Genome-wide CRISPR knockout screen reveals genes for which knockout**
 1003 **confers resistance to clodronate liposome uptake and/or induced cell death in**
 1004 ***Anopheles* cells. (a)** Clodronate liposomes induce cell death after cellular uptake by
 1005 releasing clodronate, which is enzymatically converted to adenosine 5'β-γ-
 1006 dichloromethylene triphosphate (AppCCI2p), an ATP analog that can induce apoptosis.
 1007 Assay of total ATP levels reveals higher lethality in the *Anopheles* Sua-5B-IE8-Act::Cas9-
 1008 2A-Neo cells treated with clodronate as compared to a liposome control (11-fold
 1009 difference in relative IC₅₀ values). **(b)** Schematic of a genome-wide positive selection
 1010 CRISPR knockout screen for clodronate resistance. A genome-wide CRISPR KO pool of
 1011 Sua-5B-IE8-Act::Cas9-2A-Neo cells was left untreated or treated with 16 μM liposome
 1012 (control) or 8 μM clodronate. All treatments were performed for three cycles and with
 1013 continuous drug selection of the KO pool, except for the “clodronate B” treatment group,
 1014 for which cells were subjected to an initial treatment for 4 days and then allowed to recover
 1015 in non-selective media at each treatment cycle. Genomic DNA from endpoint cell
 1016 populations was used for PCR amplification of sgRNAs, followed by NGS and enrichment

1017 analysis using the MAGeCK robust rank aggregation (RRA) algorithm. (c) Scatter plots
1018 of RRA scores for two replicates, comparing clodronate treatments A and B to control
1019 liposome treatments (left and center panels) or comparing average RRA scores between
1020 the two treatments (right panel). Left and center panels: The ‘hits’ (positive results)
1021 chosen for follow-up studies are labeled with gene symbols. Hits shown in black represent
1022 the top eight genes by RRA rank. Hits in magenta are genes of interest selected from
1023 among the top 50 hits from each screen. Right panel: only genes of interest and top hit
1024 gene of the clodronate A screen (in black) are indicated. Gene symbols shown are the
1025 symbols for orthologous human genes (symbols in all caps) or orthologous *Drosophila*
1026 genes.



1027

1028 **Fig. 3. RNAi and *in vivo* validation of candidate genes involved in clodronate**

1029 **liposome function.** (a) Genes identified from both clodronate liposome screens were

1030 selected based on their enrichment in both screens, expression in mosquito hemocyte

1031 populations⁵¹, and presumed biological function to select for candidate genes for further

1032 validation *in vivo*. Following the injection of gene-specific dsRNAs, the efficiency of RNAi

1033 was evaluated in whole mosquitoes via qRT-PCR two days post-injection (b). Expression

1034 data from three independent experiments are displayed as the mean \pm SEM and

1035 compared to GFP controls. Statistical differences were examined using an unpaired t-test

1036 for each individual gene compared to controls. (c) To determine the influence of candidate

1037 genes on clodronate liposome function, candidate genes were first silenced via the

1038 injection of dsRNAs, then control or clodronate liposomes were injected two days post-

1039 dsRNA injection. The effects of gene-silencing on clodronate liposome function were

1040 assessed by the expression of *eater* and *Nimrod B2* as a proxy to measure immune cell

1041 depletion (d). The heatmap summarizes the effects of gene-silencing on the efficacy of


1042 clodronate liposome-mediated cell ablation at 8 and 24 hours, where non-significant

1043 changes in *eater* and *Nimrod B2* expression support that the gene-silenced background

1044 impairs clodronate liposome function. Data represent three or more independent

1045 experiments. For each RNAi background, expression data were compared between


1046 control liposomes and clodronate liposomes. Differences in gene expression were
1047 examined using an unpaired t-test. For all experiments, significant differences are
1048 indicated by asterisks (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$).



1049

1050 **Fig. 4. Clodronate liposome uptake is mediated by phagocytosis.** (a) Overview of
1051 endocytic pathways, clathrin-mediated endocytosis and phagocytosis, with their
1052 respective inhibitors. To address the manner by which liposomes undergo uptake,
1053 mosquitoes were injected with the respective endocytic inhibitors (a), with the uptake of
1054 LP-DiO particles by mosquito hemocytes (immune cells) assessed at 8 hours post-
1055 injection as the percentage of LP-DiO⁺ hemocytes (b). Data were collected from individual
1056 mosquitoes (dots) and examined using Kruskal-Wallis with a Dunn's multiple
1057 comparisons test. (c) The effects of phagocytosis-inhibition (via cytochalasin D, cytoD)
1058 on clodronate liposome efficacy were evaluated using *Nimrod B2* expression as a proxy
1059 for immune cell ablation. Data from four independent experiments were analyzed using
1060 multiple unpaired t-tests to determine significance. After confirmation that cytoD treatment
1061 reduces the uptake of fluorospheres (d), candidate genes from the CRISPR screen were
1062 evaluated for potential phenotypes that similarly influence phagocytosis (e). Data from d
1063 and e display values collected from individual mosquitoes, with analysis respectively
1064 performed with individual (Mann-Whitney) or multiple comparisons (Kruskal-Wallis
1065 and Dunn's multiple comparisons test) to determine significance. These data contribute to


1066 a model (f) suggesting that liposome uptake is mediated by phagocytosis and implicates
1067 Traf6 (with AGAP gene ID number in parenthesis) in phagocytic uptake. For all
1068 experiments, significant differences are indicated by asterisks (*, $P < 0.05$; ***, $P < 0.001$;
1069 ****, $P < 0.0001$). Summary figures created with BioRender.com.



1070

1071 **Fig. 5. Clodronate liposome processing requires candidate genes involved in**
 1072 **phagolysosome formation.** (a) Overview of phagosome maturation and
 1073 phagolysosome formation after fusion with the lysosome. To confirm that phagocytosed
 1074 liposome particles undergo phagolysosome formation, immunofluorescence assays were
 1075 performed following LP-DiO injection and staining with lysosome-specific dye, LysoView
 1076 594 (b). Co-localization of LP-DiO particles (green) and the lysosome (red) support that
 1077 liposomes are processed by the formation of the phagolysosome prior to degradation.
 1078 Observations of LP-DiO⁺ cells display two distinct phenotypes, where LP-DiO particles
 1079 are punctate and remain intact (referred to as LP-DiO⁺; c), or where DiO fluorescence is
 1080 diffused (referred to as DiO⁺) suggesting that liposome particles have been degraded (d).
 1081 These LP-DiO⁺ (c) and DiO⁺ (d) phenotypes were evaluated in the gene-silenced

1082 backgrounds for each of the candidate genes identified in the CRISPR screen. Data were
1083 collected from individual mosquitoes (dots) and examined using Kruskal-Wallis with a
1084 Dunn's multiple comparisons test. (e) To further refine these observed phenotypes, we
1085 evaluated LP-DiO⁺ and DiO⁺ phenotypes following treatment with Bafilomycin A1 (BAF
1086 A1), an inhibitor of lysosome fusion with the phagosome. Data are displayed from
1087 individual mosquitoes (dots). (f) The effects of BAF A1 inhibition on clodronate liposome
1088 function were evaluated from three independent experiments using *Nimrod B2* expression
1089 as a proxy for immune cell ablation. Data in e and f were analyzed using multiple unpaired
1090 t tests to determine significance. These data contribute to a model (g) suggesting that
1091 liposome processing is mediated by formation of the phagolysosome involving Tsp3A,
1092 PGAP6, and TMEM147, which can be impaired using the inhibitor BAF A1. For all
1093 experiments, significant differences are indicated by asterisks (*, $P < 0.05$; **, $P < 0.01$;
1094 ****, $P < 0.0001$). Summary figures created with BioRender.com.



1095

1096 **Fig. 6. Summary of candidate genes involved in clodronate liposome function.**

1097 Experiments support a model in which candidate genes identified in the CRISPR screen

1098 contribute to the uptake, processing, and downstream function of clodronate liposomes

1099 in promoting immune cell ablation in *An. gambiae*. Figure created with BioRender.com.